Karen Obmaces, President and CEOAccurate Clinical Research (ACR) was built to deliver exactly that. It is one of the largest research site networks in the U.S. and has the most diverse patient population. Embedding quality and compliance into every layer of operations, ACR manages trials from Phase I through IV across numerous therapeutic areas, including rheumatology, cardiology, dermatology, gastroenterology, internal medicine, endocrinology, orthopedics, pediatrics, podiatry, urology and women’s health.
From site management and regulatory guidance to patient recruitment and trial execution, ACR serves as a crucial link between sponsors, contract research organizations (CRO) and study participants to make breakthrough treatments possible.
ACR sets itself apart by embracing a technology-first approach powered by a digital ecosystem. Its CRIO platform unifies CTMS, eSource and eReg in a single system to streamline clinical trial management. Large volumes of patient data are screened in record time by leveraging an AI-powered patient-matching platform. The process that once took months is now completed within 24 hours, accelerating study startup and improving site-sponsor collaboration.
“We are solutions-driven and deeply operationally integrated, bringing experience and agility to clinical trial execution,” says Karen Obmaces, president and CEO.
By embedding phase i into our network, we bring agility, consistency and scientific depth to early-phase research, offering a unique value proposition for our partners and sponsors
The trial data is time-stamped, transparent and remotely accessible to sponsors and monitors. They can log in to review data and documentation, reducing the need for frequent on-site visits and continuous oversight.
Turning Operational Strength into Trial Success
Agility is a core component of ACR’s operational model. Upon receiving the feasibility questionnaire and accompanying study synopsis, it inputs them into the AI platform. Protocol requirements are analyzed and matched with the most eligible candidates based on patient database compatibility and therapeutic alignment. The system then generates precise projections of potential patient availability for enrollment. These insights are submitted to the sponsor for informed site selection. The selected site undergoes a pre-study evaluation, where sponsors visit and assess ACR’s operational infrastructure and capabilities.
Equipped with best-in-class technologies, fully calibrated systems and an experienced clinical team to efficiently initiate the trial, every ACR site gives sponsors the confidence to move forward with clarity.
The corporate operations team simultaneously initiates regulatory submissions and contract and budget negotiations, typically completing the process within 10 business days. With patient identification completed during the feasibility stage, the site begins enrollment within the first week of activation—a cut above industry standards.
As a high-performing partner site, ACR invariably surpasses initial enrollment projections. Through quarterly performance metrics reviews, it delivers up to three times the initially quoted enrollment figures. In one instance, a major sponsor facing enrollment delays for a Phase II study turned to ACR. The company completed site activation within four weeks. More than 50 patients were screened in the first two months, and 35 percent of the study’s total population was enrolled.
By combining automation with insight, ACR doesn’t just move faster; it moves smarter and has become the lead enroller across the network.
Dedicated Phase I Unit for Seamless Trial Progression
ACR recently launched a Phase I unit within a Texas-based hospital. The unit is fully integrated into its network of clinical research sites to offer first-in-human (FIH) and early-phase clinical trial capabilities. It operates within the framework that has long defined the company’s operational excellence—patient-centered care and regulatory compliance.
“By embedding Phase I into our network, we bring agility, consistency and scientific depth to early-phase research, offering a unique value proposition for our partners and sponsors,” says Karen.
The facility is purpose-built to support both inpatient and outpatient clinical trials. With 30 individual rooms and multiple on-site laboratories, it offers a controlled environment for intensive monitoring and specialized procedures. Round-the-clock medical oversight and ICU-trained staff ensure high-acuity care, while services like infusion and pharmacokinetic sampling support complex study protocols. The unit functions independently from the host hospital’s institutional review board (IRB), allowing it to retain centralized regulatory control. This translates into accelerated development study timelines for sponsors and CROs.
Standard operating procedures, data platforms, regulatory workflows and staff training protocols are consistent across all sites, enabling seamless transition from FIH to later-phase trials within a unified infrastructure. ACR’s cross-site recruitment model allows sponsors and CROs to tap into a diverse, pre-screened patient database, enabling them to easily achieve challenging enrollment targets. The specialized Phase I team, skilled in suspected unexpected serious adverse reaction (SUSAR) coordination, data management and protocol-specific training, further strengthens the full-service site network.
ACR is also expanding its Phase I operations into Louisiana, where new partnerships with hospitals and care providers are laying the foundation for a freestanding facility. This strategy will bring early access trials to more patients while giving sponsors additional options for geographically distributed enrollment.
ACR’s ability to consistently deliver clinical site excellence is powered by a seasoned team of experts who work behind the scenes. Every stage is managed in-house by professionals trained to collaborate across multiple protocols and locations.
-
We are solutions-driven and deeply operationally integrated, bringing experience and agility to clinical trial execution
Its centralized research and regulatory team handles submissions across all sites, ensuring protocol fidelity, timely data capture and compliance with Good Clinical Practice standards. This consistency accelerates documentation processes and enables faster IRB turnaround times. The recruitment team identifies, screens and engages participants concurrently, while the data entry and monitoring teams maintain real-time accuracy and shorten study close-out timelines. The combined efforts of these teams enable earlier trial starts and sustained efficiency throughout execution.
ACR also employs infusion-trained nurses to administer complex biologic and investigational products, significantly expanding protocol eligibility. Safety oversight is managed by dedicated SUSAR coordinators, allowing for immediate and compliant reporting of adverse events—an essential safeguard in Phase I and other high-risk protocols.
Strategic direction from the leadership team—backed by over three decades of combined industry experience—transforms day-to-day execution into long-term value for sponsors. CFO Carlos Garcia leads financial planning for infrastructure and technology investments, while regional director Bradley Lamach oversees the operations and performance of its regional sites. Senior directors of business development, Keith Rebler and Zachary Obmaces, drive strategic partnerships and marketing initiatives.
Together, ACR’s tightly integrated team represents its enduring commitment to shaping the future of clinical research.
Putting Patients at the Heart of Research
ACR was established in 2007 as a site management organization, with a vision to bridge a critical gap in care; early patient access to emerging therapies for autoimmune diseases. In 2020, it broadened its scope to include multi-specialty trials. This evolution shifted into high gear in 2022 through a strategic partnership with Wellspire Medical Group, which united diverse physician groups and patient populations under a shared vision of cutting-edge care.
ACR’s operational success is matched by its commitment to patient inclusion, retention and access. Based in Texas, a state often described as a cultural melting pot, the company provides an ethnically and culturally diverse pool of potential study participants. This diversity is reflected in its enrollment metrics, augmenting sponsor efforts to meet FDA guidelines for inclusive research and broadening the generalizability of findings.
To ensure patient retention, ACR provides transportation assistance, accommodates visits outside of standard hours and works directly with participants to resolve any challenges that may arise during the trial. Its staff is trained to provide culturally sensitive care, and every trial is structured to support long-term patient engagement.
Its dedication to patient engagement is best highlighted in the case of a complex SLE study, where the protocol demanded intensive safety monitoring and comprehensive patient education. ACR’s team secured regulatory approvals ahead of schedule, delivered in-house training for specialized assessments and introduced weekend visits to accommodate patient schedules. The result was 100 percent patient visit adherence with zero protocol deviations.
ACR is more than a well-run clinical research operation. It is a mission-driven company rooted in the belief that well-executed protocols move the world closer to better medicine. Each study is treated as a promise to make life-changing treatments accessible to the patients who need them most. Its reputation for unmatched speed and quality stems from a culture grounded in purpose, compassion and relentless commitment.
“Research is hope, and we have the privilege of delivering that hope to patients, who are the true heroes behind every breakthrough,” says Karen.
ACR’s success is measured in patients enrolled, timelines met and regulatory standards upheld, but its impact goes far beyond metrics. Through its full-service clinical trial site model, it empowers access to potentially life-changing medications long before they reach the shelves.
Clinical Research Studies Service Info
Why is Accurate Clinical Research (ACR) recognized among Top Clinical Research Studies Services providers?
Accurate Clinical Research (ACR) has earned recognition in Clinical Research Studies Services through its large, multi-specialty site network that conducts Phase I to Phase IV clinical trials. It operates across a wide range of therapeutic areas including cardiology, dermatology, endocrinology, gastroenterology and women’s health. Its strength in Clinical Research Studies Services comes from combining patient access, site-level execution and regulatory coordination within a unified operational model. This allows sponsors to run studies with improved enrollment speed and stronger data consistency across trial phases.
What differentiates ACR in Clinical Research Studies Services?
A defining factor for ACR in Clinical Research Studies Services is its technology-enabled site management system that integrates CTMS, eSource and regulatory documentation into a single digital ecosystem. This reduces manual dependencies and improves trial visibility for sponsors and monitors. The organization also uses AI-supported patient matching to accelerate recruitment and streamline feasibility assessments. Its approach to Clinical Research Studies Services focuses on reducing study startup timelines while improving protocol adherence across multiple sites.
How does ACR support sponsors throughout clinical trial execution?
ACR supports sponsors through end-to-end involvement in Clinical Research Studies Services, beginning with feasibility analysis and extending through patient recruitment, study activation and data capture. Its teams coordinate regulatory submissions, contract management and site readiness in parallel to reduce delays. Sponsors gain access to real-time data visibility, enabling continuous oversight without frequent site visits. This structured execution model ensures that Clinical Research Studies Services remain consistent across all phases of a trial.
How do Clinical Research Studies Services from ACR improve patient recruitment and retention?
Clinical Research Studies Services at ACR are strongly focused on patient-centric trial execution. The organization leverages a diverse patient population and centralized recruitment systems to match eligible participants quickly with active studies. It also provides logistical support such as flexible scheduling and transportation assistance to improve retention. These efforts reduce dropout rates and strengthen protocol adherence, ensuring that Clinical Research Studies Services deliver reliable clinical data throughout the study lifecycle.
What role does technology and process integration play in ACR’s Clinical Research Studies Services?
Technology and process integration are central to ACR’s Clinical Research Studies Services model. The organization uses unified digital platforms that connect regulatory workflows, patient data systems and trial monitoring tools. This integration enables faster data entry, reduced documentation errors and improved compliance with Good Clinical Practice standards. By combining automation with clinical oversight, its Clinical Research Studies Services improve both operational speed and data quality.
Why are Clinical Research Studies Services from ACR relevant to modern clinical development?
Clinical Research Studies Services from ACR are increasingly relevant due to growing demand for faster, more efficient and patient-inclusive clinical trials. Its model supports accelerated study activation, higher enrollment efficiency and improved data transparency. The organization’s ability to manage complex, multi-site studies across diverse therapeutic areas makes its Clinical Research Studies Services valuable for sponsors aiming to reduce development timelines while maintaining regulatory and scientific rigor.
